Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
December 07 2023 - 7:00AM
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical
company developing and delivering novel therapies for the
management of central nervous system (CNS) disorders, is hosting a
virtual investor event and conference call today from 8 a.m. – 10
a.m. Eastern Time to provide an update on solriamfetol, a
dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI)
and trace amine-associated receptor 1 (TAAR1) agonist.
At the event, invited physician thought leaders
will discuss current and potential future indications. The Axsome
senior leadership team will provide an overview of clinical
development plans. The presenters will be available to answer
questions at the end of the presentations. To access the event,
please click here.
Expert thought leaders presenting at the event
include:
-
Craig Chepke, MD, Medical Director of Excel
Psychiatric Associates in Huntersville, N.C. and Adjunct Associate
Professor of Psychiatry for Atrium Health. Dr.
Chepke will provide an overview of TAAR1 signaling and
major depressive disorder (MDD).
-
Andrew Cutler, MD, Clinical Associate Professor of
Psychiatry SUNY Upstate Medical University. Dr. Cutler will
provide an overview of attention deficit hyperactivity disorder
(ADHD).
-
Susan McElroy, MD, Chief Research Officer and
Director of Psychopharmacology Research at the Lindner Center of
HOPE at the University of Cincinnati. Dr. McElroy will provide
an overview of binge eating disorder (BED).
- Richard
Bogan, MD, Associate Clinical Professor at the University
of South Carolina School of Medicine and at the Medical University
of South Carolina in Charleston, S.C., and is Principal of Bogan
Sleep Consultants. Dr. Bogan will provide an overview of the
SHARP study of solriamfetol in patients with excessive daytime
sleepiness (EDS) associated with obstructive sleep apnea (OSA), and
impaired cognitive function.
- Charles
Czeisler, MD, PhD, Baldino Professor of Sleep Medicine,
Director of the Division of Sleep Medicine at Harvard Medical
School and Chief of the Division of Sleep Medicine in the
Department of Medicine at Brigham and Women’s Hospital in Boston.
Dr. Czeisler will provide an overview of shift work disorder
(SWD).
Webcast and Conference Call
Information
A live webcast of the event can be accessed on
the “Webcasts & Presentations” page of the “Investors” section
of the Company’s website at www.axsome.com. To participate in the
live conference call, please dial (877) 405-1239 (toll-free
domestic). A replay of the webcast will be available for
approximately 30 days following the live event.
About Solriamfetol
Solriamfetol is a dual-acting dopamine and
norepinephrine reuptake inhibitor and trace amine-associated
receptor 1 (TAAR1) agonist. Solriamfetol is protected by a robust
patent estate with expiries out to 2042.
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical
company developing and delivering novel therapies for central
nervous system (CNS) conditions that have limited treatment
options. Through development of therapeutic options with novel
mechanisms of action, we are transforming the approach to treating
CNS conditions. At Axsome, we are committed to developing products
that meaningfully improve the lives of patients and provide new
therapeutic options for physicians. For more information, please
visit the Company’s website at axsome.com. The Company may
occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
continued commercial success of our Sunosi® and Auvelity® products
and the success of our efforts to obtain any additional
indication(s) with respect to solriamfetol and/or AXS-05; the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to
fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected revenues or expenses), futility
analyses and receipt of interim results, which are not necessarily
indicative of the final results of our ongoing clinical trials, and
the number or type of studies or nature of results necessary to
support the filing of a new drug application (“NDA”) for any of our
current product candidates; our ability to fund additional clinical
trials to continue the advancement of our product candidates; the
timing of and our ability to obtain and maintain U.S. Food and Drug
Administration (“FDA”) or other regulatory authority approval of,
or other action with respect to, our product candidates; whether
issues identified by FDA in the complete response letter may impact
the potential approvability of the Company’s NDA for AXS-07 for the
acute treatment of migraine in adults with or without aura,
pursuant to our special protocol assessment for the MOMENTUM
clinical trial; the Company’s ability to successfully defend its
intellectual property or obtain the necessary licenses at a cost
acceptable to the Company, if at all; the successful implementation
of the Company’s research and development programs and
collaborations; the success of the Company’s license agreements;
the acceptance by the market of the Company’s products and product
candidates, if approved; the Company’s anticipated capital
requirements, including the amount of capital required for the
continued commercialization of Sunosi and Auvelity and for the
Company’s commercial launch of its other product candidates, if
approved, and the potential impact on the Company’s anticipated
cash runway; unforeseen circumstances or other disruptions to
normal business operations arising from or related to COVID-19; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstance.
Axsome Contacts:
Investors:Mark JacobsonChief Operating OfficerAxsome
Therapeutics, Inc.One World Trade Center, 22nd FloorNew York,
NY 10007Tel:
212-332-3243Email: mjacobson@axsome.comwww.axsome.com
Media:Darren OplandDirector, Corporate Communications Axsome
Therapeutics, Inc.One World Trade Center, 22nd FloorNew York, NY
10007Tel: 929-837-1065Email: dopland@axsome.com
www.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2023 to Apr 2024